Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Huperzine A for Presbycusis-related Tinnitus and Cognitive Impairment
NCT03101722Enrolling by invitation
- Start
- May 2017
- Primary completion
- Sep 2030
- Modality
- Nucleic Acid-Directed Small Molecules, Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Randomised trial of Huperzine A in presbycusis, tinnitus and cognitive impairment (2 arms). Primary endpoint: Hearing function protection at 12 months. Started May 2017; status: enrolling by invitation.
02
Drugs
Huperzine A
03
Conditions
presbycusistinnituscognitive impairment
Beyond the preview
Go deeper on NCT03101722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03101722.